Today, Bluejay Therapeutics announced three upcoming presentations highlighting new data from our chronic hepatitis D and chronic hepatitis B programs at the 2024 American Association for the Study of Liver Diseases (AASLD) The Liver Meeting? in San Diego, November 15 to 19. To learn more, visit: https://bit.ly/407BGC3 #bluejaytherapeutics #hepatitisdelta #hepatitisB #AASLD #TLM24
Bluejay Therapeutics
生物技术研究
Developing innovative cures for infectious diseases with the first target indication of chronic HBV infection
关于我们
The mission of Bluejay Therapeutics is to develop innovative cures for infectious diseases with the first target indication of chronic HBV infection. Bluejay has exclusively licensed global rights to advance several HBV programs, including a best-in-class anti-HBsAg monoclonal antibody.
- 网站
-
https://www.bluejaytx.com
Bluejay Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- San Francisco Bay Area
- 类型
- 私人持股
- 创立
- 2020
地点
-
主要
获取路线
US，San Francisco Bay Area
Bluejay Therapeutics员工
动态
-
Today Bluejay Therapeutics announced positive preliminary data from the Phase 2 study of BJT-778 in patients with chronic #hepatitis D. The data presented at the 2024 EASL Congress demonstrates virological responses in 100% of treated patients. Read today’s release for full information on the results: https://bit.ly/4aRpqXU
-
-
There are only 5 days left to submit your research for consideration for The Liver Meeting in San Diego, California. Don’t wait any longer, your research deserves to be presented to thousands in the hepatology community. https://lnkd.in/gygZ7mTN
-
-
Discover all the A-TANGO activities that will take place at the #EASLCongress next week! https://lnkd.in/evFWX_Wx
-
And that's a wrap on AASLD programming at #DDW2024! Thank you for attending; we hope you had a great meeting and safe travels home!
-
-
Excited to share that we will be presenting new data from the ongoing Phase 2 trial evaluating the potential of BJT-778 for the treatment #hepatitis D at #EASL2024, along with several posters describing its preclinical profile, MOA, and pharmacokinetics and safety profile in healthy volunteers. Read today’s press release to learn more: https://bit.ly/3ysttN9
-
-
Exciting news to share again! I am so proud of the whole Bluejay team! We are making a difference.
Bluejay Announces Receipt of PRIME Designation from European Medicines Agency (EMA) for BJT-778 for the Treatment of Chronic Hepatitis Delta Virus Infection
globenewswire.com